Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

247.72USD
1:30am IST
Change (% chg)

$-0.36 (-0.15%)
Prev Close
$248.08
Open
$248.69
Day's High
$249.76
Day's Low
$242.40
Volume
4,105,177
Avg. Vol
1,158,061
52-wk High
$264.97
52-wk Low
$177.05

Latest Key Developments (Source: Significant Developments)

Lilly And Amgen Announce Manufacturing Collaboration For Covid-19 Antibody Therapies
Thursday, 17 Sep 2020 

Sept 17 (Reuters) - Amgen Inc ::LILLY AND AMGEN ANNOUNCE MANUFACTURING COLLABORATION FOR COVID-19 ANTIBODY THERAPIES.ELI LILLY - AGREEMENT WILL SIGNIFICANTLY INCREASE GLOBAL SUPPLY CAPACITY FOR LILLY'S POTENTIAL COVID-19 TREATMENTS.ELI LILLY - CURRENTLY STUDYING SEVERAL POTENTIAL NEUTRALIZING ANTIBODIES FOR PREVENTION AND/OR TREATMENT OF COVID-19 AS EITHER MONOTHERAPY OR IN COMBINATION.  Full Article

Amgen Reports Qtrly GAAP Earnings Per Share $3.05
Wednesday, 29 Jul 2020 

July 28 (Reuters) - Amgen Inc ::‍​QTRLY GAAP EARNINGS PER SHARE $3.05; QTRLY NON-GAAP EARNINGS PER SHARE $4.25; QTRLY TOTAL REVENUES UP 6% TO $6.21 BILLION.Q2 EARNINGS PER SHARE VIEW $3.82, REVENUE VIEW $6.19 BILLION -- REFINITIV IBES DATA.‍​2020 TOTAL REVENUE GUIDANCE REAFFIRMED AT $25.0 BILLION-$25.6 BILLION; SEES 2020 CAPEX TO BE ABOUT $600 MILLION.‍​2020 GAAP EPS GUIDANCE REVISED TO $10.73- $11.43; 2020 NON-GAAP EPS GUIDANCE REVISED TO $15.10-$15.75.FY2020 EARNINGS PER SHARE VIEW $15.64, REVENUE VIEW $25.43 BILLION -- REFINITIV IBES DATA.‍​GENERATED $2.7 BILLION OF FREE CASH FLOW IN Q2 VERSUS $1.3 BILLION.‍​NOTWITHSTANDING EFFECTS OF PANDEMIC, TOTAL PRODUCT SALES UP 6% FOR Q2.Q2 ‍​PRODUCT SALES UP DRIVEN BY 13% VOLUME GROWTH ACROSS NEWER PRODUCTS, INCLUDING OTEZLA, MVASI, KANJINTI, EVENITY, REPATHA.‍​SALES OF NEGATIVELY-AFFECTED PRODUCTS FELL MOST EARLY IN Q2 WITH SALES BEGINNING TO RECOVER IN LATTER WEEKS OF Q2.  Full Article

Amgen Inc's Q1 Total Revenue Increased 11% To $6.2 Billion
Friday, 1 May 2020 

April 30 (Reuters) - Amgen Inc :AMGEN INC - ‍​QTRLY TOTAL REVENUE INCREASED 11% TO $6.2 BILLION; QTRLY GAAP EPS $3.07; QTRLY NON-GAAP EPS $4.17.AMGEN INC - 2020 EPS GUIDANCE REVISED TO $10.65 - $11.45 ON A GAAP BASIS.AMGEN INC - REAFFIRMED 2020 EPS GUIDANCE OF $14.85 - $15.60 ON A NON-GAAP BASIS.AMGEN INC - 2020 TOTAL REVENUE GUIDANCE REAFFIRMED AT $25 BILLION - $25.6 BILLION.AMGEN INC - QTRLY TOTAL PRODUCT SALES INCREASED 12%.AMGEN INC - QTRLY OTEZLA SALES $479 MILLION.AMGEN INC - SEES 2020 CAPITAL EXPENDITURES TO BE ABOUT $600 MILLION.AMGEN - ENROLLMENT IS PAUSED IN CLINICAL TRIALS WHERE THERE IS UNCERTAINTY AROUND THE ABILITY OF SITES TO ENSURE SUBJECT SAFETY/DATA INTEGRITY.AMGEN SAYS OTEZLA WILL BE INVESTIGATED AS A POTENTIAL IMMUNOMODULATORY TREATMENT IN ADULT PATIENTS WITH COVID-19 IN UPCOMING TRIALS.  Full Article

Amgen Reports First Quarter 2020 Financial Results
Friday, 1 May 2020 

April 30 (Reuters) - Amgen Inc ::AMGEN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.REAFFIRMS FY 2020 NON-GAAP EARNINGS PER SHARE VIEW $14.85 TO $15.60.REAFFIRMS FY 2020 GAAP EARNINGS PER SHARE VIEW $10.65 TO $11.45.Q1 NON-GAAP EARNINGS PER SHARE $4.17.Q1 GAAP EARNINGS PER SHARE $3.07.Q1 EARNINGS PER SHARE ESTIMATE $3.76 -- REFINITIV IBES DATA.  Full Article

United Church Funds Urges Amgen Shareholders To Vote For Proposal To Require Independent Board Chair
Wednesday, 15 Apr 2020 

April 15 (Reuters) - Amgen Inc ::UNITED CHURCH FUNDS SAYS URGES AMGEN INC SHAREHOLDERS TO VOTE FOR PROPOSAL TO REQUIRE INDEPENDENT BOARD CHAIR - SEC FILING.  Full Article

Qiagen Builds On Global Collaboration With Amgen For Companion Diagnostic Development In Non-Small Cell Lung Cancer
Tuesday, 14 Jan 2020 

Qiagen NV ::QIAGEN BUILDS ON GLOBAL COLLABORATION WITH AMGEN FOR COMPANION DIAGNOSTIC DEVELOPMENT IN NON-SMALL CELL LUNG CANCER.QIAGEN NV - COLLABORATION TO DEVELOP TISSUE-BASED COMPANION DIAGNOSTICS FOR AMGEN'S INVESTIGATIONAL CANCER TREATMENT AMG 510.QIAGEN NV - QIAGEN TO PURSUE GLOBAL REGULATORY APPROVALS, INCLUDING PREMARKET APPROVAL FROM FDA FOR TISSUE-BASED THERASCREEN TEST.  Full Article

Amgen Announces 10% Increase In 2020 First Quarter Dividend
Thursday, 12 Dec 2019 

Dec 11 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 10% INCREASE IN 2020 FIRST QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.60PER SHARE.  Full Article

Bristol-Myers Squibb Receives Clearance From U.S. FTC For Celgene Acquisition
Saturday, 16 Nov 2019 

Nov 15 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES CLEARANCE FROM U.S. FEDERAL TRADE COMMISSION FOR CELGENE ACQUISITION.BRISTOL-MYERS SQUIBB CO - TRANSACTION EXPECTED TO CLOSE ON NOVEMBER 20, 2019.BRISTOL-MYERS SQUIBB CO - FTC APPROVES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA.BRISTOL-MYERS SQUIBB CO - HAS NOW SATISFIED ALL REGULATORY APPROVALS FOR CELGENE ACQUISITION.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB ALSO EXPECTS OTEZLA DIVESTITURE TO BE COMPLETED PROMPTLY FOLLOWING CLOSING OF MERGER.BRISTOL-MYERS SQUIBB - U.S. FEDERAL TRADE COMMISSION HAS ACCEPTED PROPOSED CONSENT ORDER IN CONNECTION WITH PENDING MERGER OF CO AND CELGENE.  Full Article

Nplate (Romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Friday, 18 Oct 2019 

Oct 18 (Reuters) - Amgen Inc ::NPLATE® (ROMIPLOSTIM) NOW APPROVED FOR EARLIER USE IN ADULTS WITH IMMUNE THROMBOCYTOPENIA.AMGEN - FDA APPROVED NPLATE SBLA TO INCLUDE DATA IN U.S. PRESCRIBING INFORMATION SHOWING SUSTAINED PLATELET RESPONSES IN ADULTS WITH IMMUNE THROMBOCYTOPENIA.  Full Article

Health Canada Approves Evenity For Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Tuesday, 8 Oct 2019 

Oct 8 (Reuters) - Amgen Inc ::HEALTH CANADA APPROVES EVENITY FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FOR FRACTURE.  Full Article

UPDATE 2-Lilly, Amgen partner to manufacture potential COVID-19 drugs

Sept 17 Eli Lilly and Co on Thursday partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of Lilly's drugs was shown to reduce the need for hospitalization.